企業プロフィール
ADC Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- ADCT
- 取引所:
- NYSE
- セクター:
- Biopharma
- 所在地:
- Switzerland
株価パフォーマンス
1.08 USD (-11.48%)
終値
最終更新: 2026年10月1日
403M USD
時価総額
株価変動の要因
2026年10月1日 時点で ADCT は 11.5% 下落し、$1.08 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Antibody-Drug Conjugate Company
ADC Therapeutics is a commercial-stage oncology company focused on antibody-drug conjugates. Its capabilities span clinical development, manufacturing, medical affairs, and commercialization, with a current strategic focus on the CD19-directed medicine ZYNLONTA.
ZYNLONTA Commercial Franchise
ZYNLONTA, or loncastuximab tesirine, is approved in the United States and conditionally approved in Europe for relapsed or refractory diffuse large B-cell lymphoma after at least two prior lines of systemic therapy. The company markets the product in later-line disease while working toward broader use and full approval.
Earlier-Line DLBCL Development
LOTIS-5 evaluated ZYNLONTA with rituximab, while LOTIS-7 evaluates ZYNLONTA with glofitamab in relapsed or refractory DLBCL. The company is assessing the regulatory and Phase 3 paths for these combinations following FDA feedback and completion of LOTIS-7 enrollment.
Expansion Across B-Cell Malignancies
Investigator-sponsored studies are evaluating ZYNLONTA in follicular lymphoma and marginal zone lymphoma. These programs may support publication, treatment-guideline inclusion, breakthrough designation requests, and development in disease settings beyond DLBCL.
Focused Commercial and Regulatory Organization
ADC Therapeutics has reorganized around ZYNLONTA's commercial opportunity and the regulatory work needed to sustain and expand the franchise. This narrower structure prioritizes clinical evidence, manufacturing, medical affairs, and market access for a single core asset.
今後のカタリスト
- Presentation of LOTIS-5, LOTIS-7, and marginal zone lymphoma data at the 2026 ASH Annual Meeting.
- Update on the regulatory strategy and timing for obtaining full approval of ZYNLONTA following the LOTIS-5 pre-sBLA meeting.
- Submission of LOTIS-7 and marginal zone lymphoma data for FDA Breakthrough Therapy designation in 2026.
- Presentation of updated follicular lymphoma data in the second quarter of 2027.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。